Substance / Medication

Raltegravir

Overview

Active Ingredient
raltegravir
RxNorm CUI
719872

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.
Townsend Claire L, O'Rourke John, Milanzi Edith et al. · J Int AIDS Soc · 2022
PMID: 36377082Meta-AnalysisFull text (PMC)
Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials.
Huang Yinqiu, Huang Xiaojie, Chen Hui et al. · Front Pharmacol · 2019
PMID: 31749699Meta-AnalysisFull text (PMC)
[Antiretroviral therapy containing raltegravir in HIV-infected pregnant women: Systematic review].
García-Fernández Lisset, Fiestas Fabián, Vásquez Rubén et al. · Rev Chilena Infectol · 2016
PMID: 28453028Meta-Analysis
Long-term safety from the raltegravir clinical development program.
Teppler Hedy, Brown Deborah D, Leavitt Randi Y et al. · Curr HIV Res · 2011
PMID: 21198432Meta-AnalysisFull text (PMC)
Adipose tissue transcriptome in patients switching efavirenz or a protease inhibitor to raltegravir compared to people without HIV.
Hanttu Anna M, Muniandy Maheswary, van der Kolk Birgitta W et al. · AIDS · 2025
PMID: 39874113RCT
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
Borjabad Beatriz, Inciarte Alexy, Chivite Ivan et al. · J Antimicrob Chemother · 2024
PMID: 38039097RCT
Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081.
Coutinho Conrado Milani, Warshaw Meredith G, Duarte Geraldo et al. · J Acquir Immune Defic Syndr · 2022
PMID: 36049477RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Raltegravir (substance)
SNOMED CT
429707008
UMLS CUI
C1871526
RxNorm CUI
719872

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.